Innovative drugs have been approved for listing one after another, and pharmaceutical companies are actively accelerating their commercialization

[Pharmaceutical Network Market Analysis] In the past two years, thanks to the strong support of national policies, innovative drugs of Chinese biopharmaceutical enterprises have been approved for the market one after another
.

While innovative drugs continue to be approved, many pharmaceutical companies have also begun to accelerate their commercialization
.

Taking Hairong Pharma as an example, industry analysis shows that in 2021, Hairong Pharma has more than 30 R&D pipelines of innovative drugs, improved new drugs and high-end generic drugs at different stages, many of which are in the pre-commercialization or commercialization stage.
With the commercialization of R&D results, profitability will also be improved qualitatively
.

It is reported that Hairong Pharma has continuously increased its R&D investment in recent years.
In 2020, 2021, and the first half of 2022, its R&D investment was 44.
701 million yuan, 67.
6236 million yuan, and 33.
4671 million yuan respectively.
It has invested 146 million yuan in less than three years.
Yuan
.

In the first half of the year, HR1405-01 injection, a new class 1 drug in Hairong Medicine's analgesic field, successfully carried out Phase II clinical trials and completed the enrollment of the first subject; HR1801, a class 2 new drug for injection, obtained the "Drug Clinical Trial Approval Notice" and is in the process of Carry out phase I clinical trials
.

In addition to Hairong Pharmaceuticals, up to now, CStone Pharmaceuticals has approved 4 new drugs in the past 6 years
.

While innovative drugs continue to be approved, CStone also actively builds a commercialization team and strengthens external business cooperation to continuously accelerate the commercialization layout
.

It is reported that CStone Pharmaceuticals is currently actively accelerating the implementation of Topsuwo across the country, and has been included in 5 cities Huimin Insurance and commercial health insurance.
CStone Pharmaceuticals will continue to make efforts in commercialization cooperation and cooperate with more partners.
Join hands with business innovation to further improve the accessibility and affordability of CStone's innovative drugs, benefiting more patients
.
Another example is Zai Lab, after eight years of development, driven by internal R&D and strategic cooperation, the company has established 28 differentiated and innovative product pipelines, of which 4 varieties have been commercialized.
There are 12 products in the late clinical development stage, and another 11 products have global rights
.

The company said that as of March 2022, the company's cash totaled 1.
31 billion US dollars, and the sufficient cash reserves and the company's growing product commercialization revenue will continue to support research and development investment and other expenditures
.

The industry said that the successful launch of innovative drugs is not the end, but the second half is more important, that is, to recover the cost of research and development through successful commercialization, and to obtain as much profit as possible, use it for more newer research and development projects, and promote the sustainable development of enterprises grow
.

Many pharmaceutical companies said that the company is trying to bring relevant innovative drugs to the market quickly in various ways
.

For example, Zai Lab said that in terms of commercialization exploration, the company actively cooperated with medical insurance negotiations on the one hand, and strived to allow more innovative treatments to benefit the majority of patients through medical insurance
.

On the other hand, we will actively play the role of commercial insurance payment
.

 　　For China's innovative drug industry, policy support, talent pooling, capital influx, and economic growth unleash more health needs of people, which have created opportunities for pharmaceutical companies, but at the same time, competition has also become more intense.
He said that with multiple products competing on the same stage, the ability to commercialize innovative drugs has become the key to winning the second half of the competition
.

 　　Regarding how to promote the commercialization layout, some analysts also pointed out that the commercialization layout of innovative pharmaceutical companies needs to respect the characteristics of precise target products and carry out targeted layouts
.

Through the National Medical Insurance Administration, insurance companies, pharmaceutical companies and other parties to jointly explore a multi-level security payment system, it will also promote the availability and commercialization of precision medicines including CStone
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.